Skip to main content
SpringerLink
Log in

Rifabutin has favourable DDI profile versus rifampicin

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Tuloup V, et al. Model-based comparative analysis of rifampicin and rifabutin drug-drug interaction profile. Antimicrobial Agents and Chemotherapy : 6 Jul 2021. Available from: URL: http://doi.org/10.1128/AAC.01043-21

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rifabutin has favourable DDI profile versus rifampicin. Reactions Weekly 1864, 12 (2021). https://doi.org/10.1007/s40278-021-98942-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-021-98942-5

Search

Navigation